[Actualities in prostate cancer in ASCO annual meeting 2010].
In urologic oncology, prostate cancer represented, even this year, a wide part during the ASCO 2010 meeting. In the non metastatic diseases, two phase III trials confirmed the benefit of radiotherapy combined with hormonotherapy in locally advanced stage. For patients with metastatic hormonoresistant cancer, two randomized trials will probably change the daily practice in the next months. On the one hand, denosumab versus zoledronate decreased significantly the risk of skeletal-related events in bone metastases. On the other hand, compared with mitoxantrone, cabazitaxel in docetaxel pretreated patients improved overall survival. On the contrary, docetaxel in monotherapy remains the standard of care in first line chemotherapy in castration refractory metastatic prostate cancer. Indeed, in two trials, combination of bevacizumab or calcitriol with docetaxel showed no benefit for patients with more toxicities. Finally, docetaxel-based chemotherapy was again evaluated in two other situations: biological recurrence, and hormono-sensitive metastatic stage. Preliminary results of tolerance were presented this year. No doubt that communications during future ASCO meetings would reported definitive results of efficiency of these phase III studies.
Service d'oncologie médicale, Hôpital Henri-Mondor, 94010 Créteil cedex, France. damien.pouessel@hmn.aphp.fr
D
D
Pouessel
S
S
Culine
D000726:Androgen Antagonists / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000556:secondary / Q000628:therapy; D003131:Combined Modality Therapy / Q000379:methods; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008297:Male; D008495:Medical Oncology / Q000592:standards*; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000235:genetics / Q000628:therapy*; D012955:Societies, Medical / Q000592:standards*; D014481:United States
D000726:Androgen Antagonists; D000970:Antineoplastic Agents